Literature DB >> 11062595

Hypertension and current issues in compliance and patient outcomes.

T M Zyczynski1, K S Coyne.   

Abstract

Economic and human costs associated with untreated or inadequately controlled hypertension and its complications continue to be an issue in the United States despite the availability of numerous antihypertensive agents. Knowledge of hypertension, product profiles, tolerability concerns, convenience of dosing, health-related quality of life effects, and cost of therapy are some of the factors that may influence the compliance of patients to their medication regimens. Recent reports on patient noncompliance have focused on patient-provider relationships, psychosocial barriers, home blood pressure monitoring, and electronic monitoring systems to improve blood pressure control. The use of health-related quality of life assessment in antihypertensive studies and in routine clinical practice provides another opportunity to optimize a patient's regimen for short- and long-term hypertension control in a cost-effective manner.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062595     DOI: 10.1007/s11906-996-0034-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  27 in total

1.  A clinic and community-based approach to hypertension control for an underserved minority population: design and methods.

Authors:  H J Ward; D E Morisky; N B Lees; R Fong
Journal:  Am J Hypertens       Date:  2000-02       Impact factor: 2.689

2.  Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.

Authors:  J J Caro; J L Speckman; M Salas; G Raggio; J D Jackson
Journal:  CMAJ       Date:  1999-01-12       Impact factor: 8.262

3.  Relationship between home blood pressure measurement and medication compliance and name recognition of antihypertensive drugs.

Authors:  T Ashida; T Sugiyama; S Okuno; A Ebihara; J Fujii
Journal:  Hypertens Res       Date:  2000-01       Impact factor: 3.872

4.  Changing disease definitions: implications for disease prevalence. Analysis of the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  L M Schwartz; S Woloshin
Journal:  Eff Clin Pract       Date:  1999 Mar-Apr

5.  Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial.

Authors:  L Vaur; B Vaisse; N Genes; F Elkik; C Legrand; L Poggi
Journal:  Am J Hypertens       Date:  1999-04       Impact factor: 2.689

6.  Barriers to hypertension care and control in young urban black men.

Authors:  M N Hill; L R Bone; M T Kim; D J Miller; C R Dennison; D M Levine
Journal:  Am J Hypertens       Date:  1999-10       Impact factor: 2.689

7.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

8.  Changes in physical symptoms, blood pressure and quality of life over 30 days.

Authors:  A Müller; P Montoya; R Schandry; L Hartl
Journal:  Behav Res Ther       Date:  1994-07

9.  Antihypertensive medication in clinical encounters.

Authors:  K I Kjellgren; S Svensson; J Ahlner; R Säljö
Journal:  Int J Cardiol       Date:  1998-04-01       Impact factor: 4.164

10.  Quality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine.

Authors:  A E Fletcher; C J Bulpitt; D M Chase; W C Collins; C D Furberg; T K Goggin; A J Hewett; A M Neiss
Journal:  Hypertension       Date:  1992-06       Impact factor: 10.190

View more
  7 in total

Review 1.  Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.

Authors:  Ronald Emkey
Journal:  MedGenMed       Date:  2004-07-19

2.  Using the transtheoretical model's stages of change to predict medication adherence in patients with type 2 diabetes mellitus in a primary health care setting.

Authors:  Yara Arafat; Mohamed Izham Mohamed Ibrahim; Ahmed Awaisu; Stephen Colagiuri; Yaw Owusu; Donald E Morisky; Mudather AlHafiz; Ahmed Yousif
Journal:  Daru       Date:  2019-02-07       Impact factor: 3.117

3.  Pharmacists' attitudes and perceived barriers to provision of adherence support in Australia.

Authors:  Sarab M Mansoor; Parisa Aslani; Ines Krass
Journal:  Int J Clin Pharm       Date:  2013-08-21

4.  Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.

Authors:  Stephanie C Steinberg; Richard J Faris; Cyril F Chang; Andrew Chan; Mark A Tankersley
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

5.  Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial.

Authors:  Annalisa Zoppi; Amedeo Mugellini; Paola Preti; Andrea Rinaldi; Aldo Celentano; Emma Arezzi; Marco Alberici; Roberto Fogari
Journal:  Curr Ther Res Clin Exp       Date:  2003-07

6.  Antihypertensive Medications Adherence Among Nigerian Hypertensive Subjects in a Specialist Clinic Compared to a General Outpatient Clinic.

Authors:  A A Akintunde; T S Akintunde
Journal:  Ann Med Health Sci Res       Date:  2015 May-Jun

7.  Determinants of medication adherence to antihypertensive medications among a Chinese population using Morisky Medication Adherence Scale.

Authors:  Gabrielle K Y Lee; Harry H X Wang; Kirin Q L Liu; Yu Cheung; Donald E Morisky; Martin C S Wong
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.